RxDoctor Payments Data

Lisa Pool

Nurse Practitioner · Montpelier, OHNPI 1073708434

Payments from drug & device makers

$854in general payments, 2019–2025

Across 45 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$176
  • AbbVie$110
  • Novo Nordisk$93
  • Merck$80
  • GSK$74
  • Bayer$56
  • plus $266 from 11 others

What the payments were for

  • Food & beverage$854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$854 in reported general payments places this provider in the 80th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$78,712
Medicare patients
319
Services billed
1,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide43$53,275
XareltoRivaroxaban47$37,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$34,369
EliquisApixaban37$28,756
FarxigaDapagliflozin Propanediol25$27,588
JardianceEmpagliflozin22$26,658
JanuviaSitagliptin Phosphate20$23,699
MyrbetriqMirabegron26$17,662
OzempicSemaglutide13$14,176
Janumet XrSitagliptin Phos/Metformin Hcl12$6,762
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,632
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,437
DuleraMometasone/Formoterol13$4,273
SymbicortBudesonide/Formoterol Fumarate16$3,595
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$29$53,27543 claims
GSKTrelegy Ellipta, Anoro Ellipta$74$38,80666 claims
MerckJanuvia, Janumet Xr, Dulera$80$34,73445 claims
AstraZenecaFarxiga, Symbicort$176$31,18341 claims
PfizerEliquis$32$28,75637 claims
Boehringer IngelheimJardiance$19$26,65822 claims
Novo NordiskOzempic$93$14,17613 claims
AbbVieSynthroid$110$1,85838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Montpelier

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →